


Erdheim-Chester disease and papillary thyroid carcinoma: case report of a common association in a rare disease

David Aparício¹, Nuno Martins², Carlos Leichsenring¹, Alice Rodrigues², Ana Alagoa João¹, António Soares¹, Marta Fragoso¹, Rui Marinho1, Ricardo Rocha¹, Marta Sousa¹, Serguei Gouminski¹, Cisaltina Sobrinho¹, Wilma Dias¹, Énio Afonso¹, Vasco Geraldes¹, Vítor Nunes¹



1- Cirurgia B – General Surgery Department 2 – Medicina II – Internal Medicine Department



Conclusion:

Erdheim-Chester disease + thyroid nodule

Thyroid nodule should be biopsied, even if its clinical aspect is not suspicious

If papillary carcinoma cells are BRAF V600E+

Does not mean that the Erdheim-Chester histiocytes are BRAF V600E+

If a papillary carcinoma is present

BRAF V600E should not be searched on papillary cells, because this does not change therapy

Introduction of the new armamentarium should be based on BRAF V600E positivity in the histiocytes cells

Kim S, Lee KE, et.al. BRAF V600E Mutation is associated with tumor aggressiveness in papillary cancer. World J Surg 2012. 36:310-7; Diamond EL, Dagna L, et.al. Consensus guidelines for the diagnosis and clinical management of Erdheim- Chester disease. Blood 2014. 124(4): 483-92; Cives M, Rizzo FM, et.al. Erdheim-Chester disease: A systematic review. Crit Rev Oncol/Hematol 2015, http://dx.doi.org/10.1016/j.critrvonc.2015.02.004







